Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct families of carbonic anhydrase enzymes (CAs) have so far been identified. Numerous physiological and pathological processes involve carbonic anhydrases. Many of them have the potential to be inhibited as effective therapeutic targets for the treatment of a variety of diseases, including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.
The carbonic anhydrase reaction is involved in a variety of physiological and pathological processes, including bone resorption, calcification, tumorigenicity, pH and CO2 homeostasis, electrolyte secretion in various tissues and organs, and respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs. Zn2+ metalloproteins known as -CAs are found in a wide range of organisms, including plants, prokaryotes, fungi, algae, and protozoa. Numerous diseases, including glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc., have been linked to sixteen mammalian -CA isoforms.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73767 | Carbonic anhydrase inhibitor 3 | 2758231-56-8 | Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II (carbonic anhydrase II) inhibitor that can reduce intraocular pressure in glaucoma rabbits. |
|
V73754 | Carbonic anhydrase inhibitor 4 | 2764889-93-0 | Carbonic anhydrase inhibitor 4 is a light probe/inhibitor of carbonic anhydrase. |
|
V14925 | Dorzolamide | 120279-96-1 | Dorzolamide (L671152;MK507; L671152; MK507; Trusopt) is a CAI (carbonic anhydrase inhibitors) approved for use asan anti-glaucoma agent. |
|
V85056 | FC14-584B | 1358567-64-2 | |
|
V79712 | hCA IX-IN-2 | hCA IX-IN-2 is a potent and specific inhibitor of hCA IX with a KI of 32.1 nM. | |
|
V80292 | hCA XII-IN-6 | hCA XII-IN-6 (compound 4d) is a potent hCA XII inhibitor (antagonist) with Ki of 84.2 nM. | |
|
V79713 | hCA/VEGFR-2-IN-1 | hCA/VEGFR-2-IN-1 is a potent bicarbonic anhydrase (CA) IX/XII with Kis of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. | |
|
V73748 | hCAI/II-IN-6 | 694466-00-7 | hCAI/II-IN-6 is an orally bioactive human carbonic anhydrase (CA) inhibitor. |
|
V86013 | hCAI/II-IN-7 | 14204-32-1 | |
|
V83525 | hCAII-IN-10 | ||
|
V73764 | hCAII-IN-3 | 2770927-76-7 | hCAII-IN-3 (Compound 16) is a human carbonic anhydrase (hCA) inhibitor (antagonist) with Kis of 403.8, 5.1, 10.2, and 5.2 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively. |
|
V73761 | hCAII-IN-4 | 2816080-18-7 | hCAII-IN-4 (Compound 12j) is a potent hCA II inhibitor (antagonist) with IC50 of 7.78 μM. |
|
V73762 | hCAII-IN-5 | 2816080-16-5 | hCAII-IN-5 (compound 12h) is a potent and specific inhibitor of human carbonic anhydrase II (hCA II) with IC50 of 4.55 μM. |
|
V73757 | HCAIX-IN-1 | 2389034-65-3 | HCAIX-IN-1 (compound 21e) is a potent and specific HCAIX inhibitor (antagonist) with Kis of 694.9, 126.6, 3.3, and 9.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively. |
|
V73753 | hCAIX-IN-16 | 2849348-38-3 | hCAIX-IN-16 (compound 12d) is an hCA IX inhibitor (antagonist) with Kis of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. |
|
V73756 | hCAIX-IN-18 | 2925261-76-1 | hCAIX-IN-18 (compound 30) is a carbonic anhydrase inhibitor (antagonist) with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX and hCAXII respectively. |
|
V79716 | hCAIX-IN-19 | hCAIX-IN-19 is a sulfonamide inhibitor (antagonist) with an inhibition constant (KI) of 6.2 nM for hCA IX and good selectivity for hCA I (hCA I/ hCA IX = 117). | |
|
V79714 | hCAIX/VII-IN-1 | hCAIX/VII-IN-1 is a selective hCA VII/IX inhibitor. | |
|
V73751 | hCAIX/XII-IN-3 | 2414629-94-8 | hCAIX/XII-IN-3 (compound 6q) is a potent and specific inhibitor of hCAIX and hCAXII. |
|
V79715 | hCAIX/XII-IN-6 | hCAIX/XII-IN-6 is an orally bioactive carbonic anhydrase (CA) inhibitor. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
